Future Cardia and Artella Solutions have announced the extension of their strategic partnership focused on cardiac monitoring.
The collaboration started during Future Cardia’s pre-Food and Drug Administration (FDA) stage, with the integration of Artella’s Active State Monitoring platform and the investigational implantable sensor of Future Cardia to enable secure electrocardiogram (ECG) data transmission for analysis.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The companies are now working to assess the incorporation of Artella’s remote cardiac monitoring platform into Future Cardia’s data and workflow systems.
Artella’s device-agnostic patch and telemetry platform allows both parties to test aspects such as data sharing offerings, interoperability, and the ability to enhance workflow processes.
According to the companies, this collaboration is part of ongoing research and development initiatives, in line with their aim to progress connected cardiac monitoring solutions.
Future Cardia is working on the development of an implantable device designed to capture long-term ECG data for rhythm analysis.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe device remains under regulatory review and has not yet been cleared or approved by the FDA.
Future Cardia CEO Jae Bang said: “Future Cardia was founded on the belief that long-term physiologic data can enhance our understanding of cardiac health.
“Our collaboration with Artella represents an important step in exploring how implantable and external monitoring technologies can work together to advance data integration and clinical workflow capabilities.”
Digital healthcare company Artella provides services focused on remote cardiac monitoring, including patch-based technology and AI tools to help detect cardiac rhythm abnormalities. The company also offers a centralised system intended to support data review for clinicians and enhance workflow efficiency.
Artella Solutions CEO and co-founder Sepand Moshiri said: “Future Cardia is bringing an implantable solution to a market that urgently needs innovation.
“Artella and its holding company CorMedica Group were built to partner with technologies like this in which data, automation, clinical oversight, and elite customer service can meaningfully change outcomes for patients and providers.”
